Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Nov 21, 2019 | TCTMD Articles

PHILADELPHIA, PA—The first phase III study of a novel drug that inhibits the bromodomain extra-terminal (BET) protein pathway through epigenetic modification failed to meet its primary endpoint in a population of post-ACS patients with diabetes and low HDL cholesterol. But experts agreed that the agent still holds promise for other patient groups.